Halofuginone hydrobromide

• Description:

  Halofuginone is an an ATP-dependent inhibitor prolyl-tRNA synthetase (Ki of 18.3 nM). Halofuginone attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Blocks expression of MMP2 and inhibits ECM invasion in vitro and lung metastasis by bladder cancer cells in mice. Also inhibits the development of Th17-driven autoimmunity in a mouse model of multiple sclerosis by activating the amino acid response (AAR) pathway.

• Shipping Conditions:

  Gel Pack

• Storage Conditions:

  -20ºC

• Shelf Life:

  36 months